Spots Global Cancer Trial Database for cabazitaxel xrp6258
Every month we try and update this database with for cabazitaxel xrp6258 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy | NCT01497964 | Gastric Cancer | cabazitaxel XRP... | 18 Years - | Sanofi | |
| Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | NCT02074137 | Prostate Cancer... | CABAZITAXEL XRP... Prednisone Prednisolone | 18 Years - | Sanofi | |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | NCT01527929 | Neoplasm Malign... | Cabazitaxel XRP... | 18 Years - | Sanofi | |
| Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer | NCT02441894 | Prostate Cancer | CABAZITAXEL XRP... PEG-G-CSF Prednisolone Dexchlorphenira... Ranitidine Metoclopramide,... Dexamethasone | 20 Years - | Sanofi | |
| Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy | NCT01497964 | Gastric Cancer | cabazitaxel XRP... | 18 Years - | Sanofi | |
| Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer | NCT02441894 | Prostate Cancer | CABAZITAXEL XRP... PEG-G-CSF Prednisolone Dexchlorphenira... Ranitidine Metoclopramide,... Dexamethasone | 20 Years - | Sanofi | |
| Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent | NCT02485691 | Prostate Cancer... | cabazitaxel XRP... enzalutamide abiraterone ace... prednisone | 18 Years - | Sanofi | |
| Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT01511536 | Prostate Cancer | Cabazitaxel XRP... Abiraterone ace... Prednisone 5 mg | 18 Years - | Sanofi | |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | NCT01527929 | Neoplasm Malign... | Cabazitaxel XRP... | 18 Years - | Sanofi | |
| Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide | NCT02379390 | Prostate Cancer... | Cabazitaxel XRP... Ezalutamide Abiraterone ace... Prednisone | 18 Years - | Sanofi | |
| Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer | NCT02074137 | Prostate Cancer... | CABAZITAXEL XRP... Prednisone Prednisolone | 18 Years - | Sanofi | |
| Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT01511536 | Prostate Cancer | Cabazitaxel XRP... Abiraterone ace... Prednisone 5 mg | 18 Years - | Sanofi | |
| Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | NCT01527929 | Neoplasm Malign... | Cabazitaxel XRP... | 18 Years - | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
